Revax Biotech Ultra-Low Dose Vaccine Technology can make World Vaccination a Reality
Revax Biotech announce their response to the G7/WHO Challenge enabling vaccines to be available to meet existing or emerging respiratory pandemic threats in 100 days or less. Revax Biotech is a UK based innovative vaccine company with game-changing, patented technology that uses inhalation to deliver 1/100,000th of the dose
27/10/2023